Table 2_Is full adherence mandatory? Real-world outcomes of completing perioperative chemo

Zhoujunyi Tian's dataset compares recurrence-free survival, overall survival, and adverse event rates between patients who completed a full perioperative chemoimmunotherapy regimen and those who did not. It includes data from 164 patients with resectable non-small cell lung cancer at clinical stage IB-IIIB. The dataset was last updated on 2026-05-28.

Use Cases

• Compare recurrence-free survival between treatment completion groups based on Kaplan-Meier analysis.
• Assess overall survival outcomes based on completion status of perioperative chemoimmunotherapy.
• Analyze the incidence of adverse events based on reported any-grade and Grade 3/4 AE rates.
• Identify predictors of recurrence based on pathological nodal status and other variables.
• Conduct subgroup analysis for specific patient cohorts based on age and ECOG performance status.

Strengths

• Dataset includes 164 patient records.
• Analysis uses Inverse Probability of Treatment Weighting to adjust for baseline characteristics.
• Specific hazard ratios and confidence intervals are reported for key predictors.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 17.1 KB, indicating limited scope.

Provenance

Source

Zhoujunyi Tian via figshare

Collection Method

Retrospective study of patients with resectable non-small cell lung cancer who received neoadjuvant chemoimmunotherapy followed by surgery.

Freshness

Last updated 2026-05-28 04:45:41; freshness should be verified.